Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62020TA0635

    Case T-635/20: Judgment of the General Court of 6 October 2021 — Dermavita Company v EUIPO — Allergan Holdings France (JUVÉDERM VYBRANCE) (EU trade mark — Invalidity proceedings — EU word mark JUVÉDERM VYBRANCE — Late payment of the appeal fee — Inadmissibility of the appeal before the Board of Appeal — Article 101(4) of Regulation (EU) 2017/1001 — Article 106(1)(b) of Regulation 2017/1001 — Restitutio in integrum)

    OJ C 481, 29.11.2021, p. 27–27 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    29.11.2021   

    EN

    Official Journal of the European Union

    C 481/27


    Judgment of the General Court of 6 October 2021 — Dermavita Company v EUIPO — Allergan Holdings France (JUVÉDERM VYBRANCE)

    (Case T-635/20) (1)

    (EU trade mark - Invalidity proceedings - EU word mark JUVÉDERM VYBRANCE - Late payment of the appeal fee - Inadmissibility of the appeal before the Board of Appeal - Article 101(4) of Regulation (EU) 2017/1001 - Article 106(1)(b) of Regulation 2017/1001 - Restitutio in integrum)

    (2021/C 481/38)

    Language of the case: English

    Parties

    Applicant: Dermavita Company S.a.r.l. (Beirut, Lebanon) (represented by: D. Todorov, lawyer)

    Defendant: European Union Intellectual Property Office (represented by: E. Markakis and V. Ruzek, acting as Agents)

    Other party to the proceedings before the Board of Appeal of EUIPO: Allergan Holdings France SAS (Courbevoie, France)

    Re:

    Action brought against the decision of the Fourth Board of Appeal of EUIPO of 24 August 2020 (Case R 1014/2020-4), relating to invalidity proceedings between Dermavita Company and Allergan Holdings France.

    Operative part of the judgment

    The Court:

    1.

    Dismisses the action;

    2.

    Orders Dermavita Company S.a.r.l. to pay the costs.


    (1)  OJ C 443, 21.12.2020.


    Top